All In Biotech

Drug Trial Radar · NCT07325526

A Study to Test Whether BI 3802876 is Tolerated in People With Compensated Liver Cirrhosis Due to Metabolic Dysfunction- Associated Steatohepatitis (MASH)

A Phase IIa Double-blind, Placebo-controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 3802876 in Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

Feb 27, 2026

Primary completion

Aug 5, 2027

Study completion Aug 5, 2027

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Jan 8, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is open to adults with a type of confirmed liver condition called compensated cirrhosis due to Metabolic Dysfunction-Associated Steatohepatitis (MASH). The purpose of this study is to find out how well a study medicine called BI 3802876 is tolerated in people with this condition. The study looks at how different doses of BI 3802876 are handled by the body. BI 3802876 is being developed to improve liver health in people living with this liver condition. Participants are put in 3 different dose groups randomly, which means by chance. Participants within a group get BI 3802876 or placebo. Placebo looks like BI 3802876 but does not contain any medicine. Participants have more than twice the chance of receiving BI 3802876 than placebo. The study medicine is given as an infusion into a vein. Participants are in the study for about half a year. During this time, they visit the study site 12 times. At 2 visits, participants get the study medicine. Doctors collect information on any health problems and take blood samples to check how BI 3802876 is handled by the body. They compare results between the groups.

Conditions

  • Liver Cirrhosis

Interventions

  • BI 3802876Drug

    BI 3802876

  • PlaceboDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Occurrence of any Adverse Events (AEs)Time frame: up to 134 days

Locations

28 sites in 2 countries. Site status is shown where the registry gives one.

  • Arizona Clinical Trials - Chandler

    Chandler, Arizona · Recruiting

  • Southern California Research Center

    Coronado, California · Recruiting

  • Velocity Clinical Research, San Diego

    La Mesa, California · Recruiting

  • Kaiser Permanente - Los Angeles Medical Center

    Los Angeles, California · Recruiting

  • Catalina Research Institute, LLC

    Montclair, California · Recruiting

  • Peak Gastroenterology Associates

    Colorado Springs, Colorado · Recruiting

  • Mayo Clinic

    Jacksonville, Florida · Recruiting

  • Schiff Center Liver Diseases

    Miami, Florida · Recruiting

  • Panax Clinical Research

    Miami Lakes, Florida · Recruiting

  • Covenant Metabolic Specialists, LLC - University Park

    University Park, Florida · Recruiting

  • Centricity Research Columbus Georgia Multispecialty

    Columbus, Georgia · Recruiting

  • University of Iowa Hospitals and Clinics

    Iowa City, Iowa · Recruiting

  • University of Kansas Medical Center

    Kansas City, Kansas · Recruiting

  • Johns Hopkins Hospital

    Baltimore, Maryland · Not yet recruiting

  • Mayo Clinic, Rochester

    Rochester, Minnesota · Recruiting

  • Columbia University Medical Center

    New York, New York · Recruiting

  • Lucas Research, Inc.

    Morehead City, North Carolina · Recruiting

  • Medical University of South Carolina

    Charleston, South Carolina · Recruiting

  • Nashville General Hospital

    Nashville, Tennessee · Recruiting

  • Texas Clinical Research Institute, LLC

    Arlington, Texas · Recruiting

  • Epic Medical Research - Carrollton

    Carrollton, Texas · Recruiting

  • The Liver Institute at Methodist Dallas

    Dallas, Texas · Recruiting

  • Baylor Scott & White Research Institute

    Dallas, Texas · Not yet recruiting

  • Epic Medical Research - Fort Worth

    Fort Worth, Texas · Recruiting

  • Houston Methodist Hospital

    Houston, Texas · Recruiting

  • Pioneer Research Solutions, Inc.

    Houston, Texas · Recruiting

  • American Research Corporation at the Texas Liver Institute

    San Antonio, Texas · Recruiting

  • University of Alberta Hospital (University of Alberta)

    Edmonton, Alberta, Canada · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.